Last week, when the Treasury effectively scuttled the Pfizer-Allergan merger, there was much rejoicing: politicians and pundits alike were thrilled that tax inversion greed had been stopped, and that companies like Pfizer would have to “pay their fair share.”  Investors

This blog was written by Christiana Stamoulis, CFO and Head of Corporate Development at Unum, as part of the “From The Trenches” feature of LifeSciVC. In June 2015 Unum Therapeutics closed a $65M a Series B round, bringing in capital

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here). This transformative deal is the culmination of over five years of work on

Today we announced the acquisition of Padlock Therapeutics by BMS for up to $600M in total deal value (here), bringing a bittersweet end to a great startup story and the start of a promising and likely productive portfolio for BMS.

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much of the discussion I have had had with my colleagues in publicly traded biotech companies over the last

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. Love it or hate it, no one can deny that Über has revolutionized the fundamental nature of the taxi

For startup and emerging biotech companies, corporate venture capital and direct corporate equity investing are critically important contributors on the spectrum of funding sources – and over the past fifteen years, their involvement as investors in young biotech companies appears

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Infectious disease has had an ebb and flow relationship with our general awareness; epidemics such as Zika, Ebola, and

It’s hard to believe how time flies, but I started this LifeSciVC biotech-blogging experiment five years ago today. Since that initial post in March 2011, exactly 250 blogs have gone live, making it an opportune time to step back and

This blog was written by Jason Gardner, Atlas EIR and founding CEO of a new stealth-stage startup, as part of the From The Trenches feature of LifeSciVC. What are you doing? This is the most frequent yet simple question that

This blog was written by Jose-Carlos Gutiérrez-Ramos, CEO of Synlogic, as part of the “From The Trenches” feature of LifeSciVC. When I was invited to contribute to this blog, I was determined to write first about patients with Rare Diseases and

Biotech and the overall equity markets have been under siege the past few months from macro forces, like oil and the economy, as well as sector-specific concerns like drug pricing. After watching the carnage in 2016 wreck havoc with small